[1]孙浩,李姣,毕宏生,等.阿柏西普对葡萄膜黑色素瘤细胞的作用及其机制研究[J].眼科新进展,2022,42(4):284-288.[doi:10.13389/j.cnki.rao.2022.0057]
　SUN Hao,LI Jiao,BI Hongsheng,et al.Effect and mechanism of aflibercept on uveal melanoma cells[J].Recent Advances in Ophthalmology,2022,42(4):284-288.[doi:10.13389/j.cnki.rao.2022.0057]
点击复制

阿柏西普对葡萄膜黑色素瘤细胞的作用及其机制研究/HTML
分享到：

《眼科新进展》[ISSN:1003-5141/CN:41-1105/R]

卷:
42卷
期数:
2022年4期
页码:
284-288
栏目:
实验研究
出版日期:
2022-04-05

文章信息/Info

Title:
Effect and mechanism of aflibercept on uveal melanoma cells
作者:
孙浩; 李姣; 毕宏生; 王兴荣
250002　山东省济南市，山东中医药大学（孙浩） ； 276000　山东省临沂市，兰陵县人民医院 （孙浩）; 250002　山东省济南市，山东中医药大学附属眼科医院、山东省眼病防治研究院（李姣，毕宏生，王兴荣）
Author(s):
SUN Hao1; 2; LI Jiao3; BI Hongsheng3; WANG Xingrong3
1.Shandong University of Traditional Chinese Medicine,Jinan 250002，Shandong Province，China
2.Lanling County People’s Hospital of Linyi City,Linyi 276000，Shandong Province， China
3.Affiliated Eye Hospital of Shandong University of Traditional Chinese Medicine, Shandong Institute of Eye Disease Control，Jinan 250002，Shandong Province， China
关键词:
阿柏西普; 葡萄膜黑色素瘤; VEGF; 作用机制
Keywords:
aflibercept;  uveal melanoma;  vascular endothelial growth factor;  mechanism of action
分类号:
R773.9
DOI:
10.13389/j.cnki.rao.2022.0057
文献标志码:
A
摘要:
目的　探索阿柏西普对葡萄膜黑色素瘤细胞的作用及其机制。方法　将B16F10细胞（葡萄膜黑色素瘤细胞）分为实验组和对照组，对照组不使用药物处理，实验组分别用0.2 g·L-1、2.0 g·L-1、4.0 g·L-1阿柏西普进行干预。通过实时细胞电子分析系统(RT-CES)、CCK-8法探讨不同剂量的阿柏西普对葡萄膜黑色素瘤细胞生长过程的影响；ELISA分析阿柏西普对葡萄膜黑色素瘤细胞中VEGF-A含量的影响；RT-PCR检测不同剂量阿柏西普对葡萄膜黑色素瘤细胞VEGF-A mRNA表达的影响；流式细胞仪分析不同剂量阿柏西普对葡萄膜黑色素瘤细胞周期和凋亡的影响。结果　0.2 g·L-1、2.0 g·L-1、4.0 g·L-1的阿柏西普作用B16F10细胞 24 h 后，细胞存活率分别下降至(95.10±1.76)%、(87.33±2.20)%和(74.36±1.67)%。RT-PCR检测结果显示：阿柏西普能够下调细胞中VEGF-A mRNA的表达；ELISA检测结果表明，阿柏西普可抑制细胞中VEGF-A的水平，其中4.0 g·L-1阿柏西普抑制作用最为明显。此外，与对照组［细胞凋亡率0%，G1期细胞比例为(27.60±0.36)%］相比，0.2 g·L-1、2.0 g·L-1、4.0 g·L-1阿柏西普干预24 h后，B16F10细胞凋亡率分别升高为3.51%、11.10%和14.77%，G1期细胞比例分别升高至(64.09±0.34)%、(66.02±0.65)%、(67.49±0.33)%，差异均有统计学意义（均为P<0.05）。结论　阿柏西普对葡萄膜黑色素瘤细胞有显著抑制作用，其作用机制为抑制细胞中VEGF-A水平，从而诱导细胞发生凋亡和S期阻滞，其作用具有浓度依赖性。
Abstract:
Objective　To investigate the effect and mechanism of aflibercept on uveal melanoma cells. Methods　B16F10 cells (uveal melanoma cells) were divided into the experimental group and control group. Cells in the control group were not treated with drugs, while cells in the experimental group were intervened with 0.2 g·L-1, 2.0 g·L-1, and 4.0 g·L-1 aflibercept. Real-time cell electronic sensing (RT-CES) and CCK-8 assays were used to explore the effect of different doses of aflibercept on the growth process of uveal melanoma cells. ELISA assay was performed to investigate the effect of aflibercept on the content of vascular endothelial growth factor A (VEGF-A) in uveal melanoma cells, real-time polymerase chain reaction (RT-PCR) assay was performed to investigate the effects of different doses of aflibercept on the mRNA expression of VEGF-A in uveal melanoma cells, and flow cytometry was performed to investigate the effects of different doses of aflibercept on cycle and apoptosis of uveal melanoma cells.Results　It was found that the survival rates of B16F10 cells treated by 0.2 g·L-1, 2.0 g·L-1 and 4.0 g·L-1 of aflibercept for 24 h fell to (95.10±1.76) %, (87.33±2.20) % and (74.36±1.67) %, respectively. RT-PCR assay results showed that aflibercept down-regulated the mRNA expression of VEGF-A in cells. ELISA assay results showed that aflibercept inhibited VEGF-A levels in cells, with 4.0 g·L-1 aflibercept having the most significant inhibitory effect. In addition, compared with the control group ［apoptosis rate: 0%, proportion of cells in G1 phase: (27.60±0.36) %］, the apoptosis rates of B16F10 cells in the experimental group increased to 3.51 %, 11.10% and 14.77% after being intervened by 0.2 g·L-1, 2.0 g·L-1 and 4.0 g·L-1 aflibercept for 24 h, respectively, and the proportion of cells in G1 phase increased to (64.09±0.34) %, (66.02±0.65) % and (67.49±0.33) %, with statistically significant differences (all P<0.05).Conclusion　Aflibercept shows significant inhibitory effects on uveal melanoma cells by inhibiting the VEGF-A levels and inducing apoptosis and S-phase arrest in a concentration-dependent manner.

参考文献/References:

［1］　RUSK ,HECOV L,KASL Z,SOBOTOV M,HAUER L.Therapy of uveal melanoma:a review［J］.Cesk Slov Oftalmol,2020,77(1):1-13.
［2］　WU M Y,LAI T T,LIAO W T,LI C J.Clinic opathological and prognostic significance and molecular mechanisms governing uveal melanoma［J］.Ther Adv Med Oncol,2020,12:1-12.
［3］　FOLKMAN J.Role of angiogenesis in tumor growth and metastasis［J］.Semin Oncol,2002,29(6 Suppl 16):15-18.
［4］　FERRARA N,HILLAN K J,GERBER H P,NOVOTNY W.Discovery and development of bevacizumab,an anti-VEGF antibody for treating cancer［J］.Nat Rev Drug Discov,2004,3(5):391-400.
［5］　SARWAR S,CLEARFIELD E,SOLIMAN M K,SADIQ M A,BALDWIN A J,HANOUT M，et al.Aflibercept for neovascular age-related macular degeneration［J］.Cochrane Database Syst Rev,2016,12(8):2.
［6］　GONZALEZ N S,SALV F,ROS J,BARAIBAR I,MARMOLEJO D,VALDIVIA A，et al.Up-to-date role of aflibercept in the treatment of colorectal cancer［J］.Expert Opin Biol Ther,2021,21(10):1315-1324.
［7］　BURR J M,MITRY E,RACHET B,COLEMAN M P.Survival from uveal melanoma in England and Wales 1986 to 2001［J］.Ophthalmic Epidemiol,2007,14(1):3-8.
［8］　CARVAJAL R D,SCHWARTZ G K,TEZEL T,MARR B,FRANCIS J H,NATHAN P D.Metastatic disease from uveal melanoma:treatment options and future prospects［J］.Br J Ophthalmol,2017,101(1):38-44.
［9］　XU L T,FUNCHAIN P F,BENA J F,LI M,TARHINI A,BERBER E，et al.Uveal melanoma metastatic to the liver:treatment trends and outcome［J］.Ocul Oncol Pathol,2019,5(5):323-332.
［10］　MITTAL K,EBOS J,RINI B.Angiogenesis and the tumor microenvironment:vascular endothelial growth factor and beyond［J］.Semin Oncol,2014,41(2):235-251.
［11］　FAKHREJAHANI E,TOI M.Antiangiogenesis therapy for breast cancer:an update and perspectives from clinical trials［J］.Jpn J Clin Oncol,2014,44(3):197-207.
［12］　李自显,徐刚,王亚楠,杨文义.VEGF基因沉默联合唑来膦酸抑制胃癌细胞增殖和迁移的机制［J］.现代肿瘤医学,2019,27(20):3597-3601.
LI Z X，XU G，WANG Y N，YANG W Y.Mechanisms of targeting VEGF gene combined with zoledronic acid on proliferation and migration of hepatocellular carcinoma cells［J］.Modern Oncol，2019,27(20):3597-3601.
［13］　CHEKHONIN V P,SHEIN S A,KORCHAGINA A A,GURINA O I.VEGF in tumor progression and targeted therapy［J］.Curr Cancer Drug Targets,2013,13(4):423-443.
［14］　PAPADOPOULOS Z.Aflibercept:a review of its effect on the treatment of exudative age-related macular degeneration［J］.Eur J Ophthalmol,2019,29(4):368-378.
［15］　AVERY R L,CASTELLARIN A A,STEINLE N C,DHOOT D S,PIERAMICI D J,SEE R，et al.Systemic pharmacokinetics and pharmacodynamics of intravitreal aflibercept，bevacizu-mab and ranibizumab［J］.Retina,2017,37(10):1847-1858.
［16］　CHU Q S.Aflibercept (AVE0005):an alternative strategy for inhibiting tumour angiogenesis by vascular endothelial growth factors［J］.Expert Opin Biol Ther,2009,9(2):263-271.
［17］　GIORDANO G,FEBBRARO A,VENDITTI M,CAMPIDOGLIO S,OLIVIERI N,RAIET A K，et al.Targeting angiogenesis and tumor microenvironment in metastatic colorectal cancer:role of aflibercept［J］.Gastroenterol Res Pract,2014,7(21):1-13.

相似文献/References:

[1]李明 张永喜 王胜根.葡萄膜黑色素瘤术后自体细胞因子诱导的杀伤细胞治疗效果观察[J].眼科新进展,2012,32(8):000.
[2]祁海燕,苏学刚.LncRNA MT1JP对葡萄膜黑色素瘤细胞迁移和侵袭的影响[J].眼科新进展,2017,37(6):531.[doi:10.13389/j.cnki.rao.2017.0134]
　QI Hai-Yan,SU Xue-Gang.Effects of LncRNA MT1JP on migration and invasion of uveal melanoma cells[J].Recent Advances in Ophthalmology,2017,37(4):531.[doi:10.13389/j.cnki.rao.2017.0134]
[3]李娜,曹娟,郁继国,等.miR-26a对葡萄膜黑色素瘤细胞增殖、凋亡、迁移和侵袭的影响及机制研究[J].眼科新进展,2017,37(7):619.[doi:10.13389/j.cnki.rao.2017.0157]
　LI Na,CAO Juan,YU Ji-Guo,et al.Effects of miR-26a on proliferation，apoptosis，migration and invasion of uveal melanoma cell and its mechanism[J].Recent Advances in Ophthalmology,2017,37(4):619.[doi:10.13389/j.cnki.rao.2017.0157]
[4]邹洪强,田洪芹,张艳平,等.阿柏西普治疗眼底血管性疾病的临床研究新进展[J].眼科新进展,2017,37(9):894.[doi:10.13389/j.cnki.rao.2017.0227]
　ZOU Hong-Qiang,TIAN Hong-Qin,ZHANG Yan-Ping,et al.Recent advances in clinical research on aflibercept treating fundus vascular diseases[J].Recent Advances in Ophthalmology,2017,37(4):894.[doi:10.13389/j.cnki.rao.2017.0227]
[5]毛英,白海霞,畅颖,等.星形胶质细胞活化基因-1（AEG-1）在葡萄膜黑色素瘤中的表达及其与临床组织病理学的关系[J].眼科新进展,2018,38(2):121.[doi:10.13389/j.cnki.rao.2018.0026]
　MAO Ying,BAI Hai-Xia,CHANG Ying,et al.Expression of astrocyte elevated gene-1 (AEG-1) in uveal melanoma and its relationship with clinical histopathology[J].Recent Advances in Ophthalmology,2018,38(4):121.[doi:10.13389/j.cnki.rao.2018.0026]
[6]郑磊,温佳敏,张国明.葡萄膜黑色素瘤的药物治疗研究现状[J].眼科新进展,2018,38(2):188.[doi:10.13389/j.cnki.rao.2018.0043]
　ZHENG Lei,WEN Jia-Min,ZHANG Guo-Ming.Research advances in the treatment for uveal melanoma[J].Recent Advances in Ophthalmology,2018,38(4):188.[doi:10.13389/j.cnki.rao.2018.0043]
[7]邵毅.阿柏西普治疗新生血管性年龄相关性黄斑变性——2017欧洲视网膜专家学会共识解读[J].眼科新进展,2018,38(7):601.[doi:10.13389/j.cnki.rao.2018.0142]
　SHAO Yi.Aflibercept treatment for neovascular age related macular degeneration—The Interpretation of The Consensus of European Society of Retina Specialists，2017[J].Recent Advances in Ophthalmology,2018,38(4):601.[doi:10.13389/j.cnki.rao.2018.0142]
[8]伍雪,张锐.葡萄膜黑色素瘤相关炎症浸润细胞及免疫治疗[J].眼科新进展,2019,39(3):282.[doi:10.13389/j.cnki.rao.2019.0064]
　WU Xue,ZHANG Rui.Inflammatory infiltrating cells related to uveal melanoma and its immunotherapy[J].Recent Advances in Ophthalmology,2019,39(4):282.[doi:10.13389/j.cnki.rao.2019.0064]
[9]卢谦益.阿柏西普经玻璃体内注射治疗糖尿病黄斑水肿的临床疗效[J].眼科新进展,2019,39(4):340.[doi:10.13389/j.cnki.rao.2019.0076]
　LU Qian-Yi.Intravitreal aflibercept injection for the treatment of diabetic macular edema[J].Recent Advances in Ophthalmology,2019,39(4):340.[doi:10.13389/j.cnki.rao.2019.0076]
[10]余霄.葡萄膜黑色素瘤的治疗现状[J].眼科新进展,2019,39(4):398.[doi:10.13389/j.cnki.rao.2019.0091]
　YU Xiao.Management status of uveal melanoma[J].Recent Advances in Ophthalmology,2019,39(4):398.[doi:10.13389/j.cnki.rao.2019.0091]

备注/Memo

备注/Memo:
山东省医药卫生科技发展计划项目（编号：2018ws194）；山东省自然科学基金面上项目（编号：ZR2020MH393）
更新日期/Last Update: 2022-04-05